Omega-3 and Atrial Fibrillation: What 34 Trials Actually Show

For most people taking a standard fish-oil supplement, the latest and largest analysis does not find a statistically significant increase in atrial fibrillation (AF). The concern remains relevant for people taking pharmacological doses, especially those with high cardiovascular risk. Those are different questions, and earlier headlines often treated them as one.

An updated 2026 meta-analysis pooled 34 randomized controlled trials with 114,326 participants. It found no significant increase in AF at doses of 1,500 mg per day or less of combined EPA and DHA. In the subgroup taking more than 1,500 mg per day and already at high cardiovascular risk, however, the estimated odds ratio was about 1.48, with an absolute AF-risk increase of about 0.8%.

That distinction changes the practical answer. A typical supplement dose and a 4-gram prescription-style regimen in a high-risk cardiac population should not share the same warning label.

Why the earlier alarm looked broader than it was

Previous meta-analyses, including one by Gencer et al. cited in the newer paper, combined seven or eight trials and reported a 25% higher AF risk with omega-3 treatment. Those analyses addressed the trials available at the time. Their limitation was selection: they included trials in which AF was a prespecified cardiovascular endpoint.

That criterion favored large studies of pharmacological-dose omega-3 products—such as 4 g per day of icosapent ethyl or 4 g per day of EPA+DHA carboxylic acid—in people with substantial pre-existing cardiovascular risk. It did not represent the ordinary person taking a modest over-the-counter EPA+DHA dose.

The newer analysis searched nine databases, ClinicalTrials.gov, and the CDEK registry, then captured AF reported as an adverse event as well as AF recorded as a planned endpoint. Its eligibility criteria required at least 500 mg per day of EPA+DHA, at least 12 months of follow-up, age 50 or older, and no known AF at baseline. Expanding the evidence base from eight or fewer trials to 34 shifted the overall interpretation: standard-dose use was not associated with a statistically significant increase in AF.

The best current estimate is dose- and population-specific: no significant AF signal at up to 1,500 mg per day of EPA+DHA, but a higher estimated risk in high-dose users with high baseline cardiovascular risk.

The high-dose finding still deserves a clinical conversation

The high-dose subgroup result is not a reason to panic, but it is not decorative fine print either. An odds ratio of about 1.48 sounds dramatic until it is paired with the reported absolute increase of about 0.8%. Relative and absolute effects answer different questions: the first describes the proportional difference; the second helps show the likely scale of added events.

For someone using more than 1,500 mg per day—particularly a 4-g prescription regimen—with structural heart disease, prior AF, or several AF risk factors, the decision belongs with the prescriber who knows why the drug was prescribed. This analysis does not provide enough trial-level information to calculate a complete tradeoff between cardiovascular benefits, mortality, and AF risk in that subgroup.

The proposed dose threshold has biological plausibility. Gram-level dosing can produce much higher EPA concentrations in tissues than standard supplementation, which could affect atrial ion-channel behavior. But plausible biology is not direct proof. The available evidence does not independently establish a human electrophysiology threshold at 1,500 mg per day, nor does it settle whether EPA-only and EPA+DHA products have different AF effects.

What the meta-analysis can and cannot settle

Its size is a major strength, but the primary analysis is a preprint, not yet peer-reviewed. It was prospectively registered and incorporated information beyond published papers, which reduces the risk that only the most visible trials shape the result. It also introduces uncertainty: registry-based serious-adverse-event reports are not peer-reviewed and may have incomplete or inconsistently reported event counts.

AF ascertainment also varied across trials. Investigators used combinations of central adjudication, ECG monitoring, medical records, insurance claims, and participant-reported adverse events. These approaches do not detect AF with equal sensitivity or specificity. The analysis also identifies informative censoring as a concern in earlier work: if treated participants survived longer, they could accumulate more time in which AF might be detected. Whether the newer pooled method fully removes that bias remains uncertain.

Finally, every included trial enrolled adults 50 or older without known AF at baseline. The findings do not automatically extend to younger supplement users, although their lower baseline AF risk would make the absolute risk question different as well.

Fish is more than an omega-3 delivery system

The supplement question should not swallow the food question. A review of fish consumption and metabolic health describes fish as a source of omega-3 fatty acids, iodine, selenium, vitamin D, taurine, carnitine, and high-quality protein. A capsule can supply fatty acids; it cannot reproduce that food matrix.

This does not prove that eating fish prevents AF or that fish has a different AF-risk profile than supplements. Neither conclusion has direct support here. It does mean that choosing fish for dietary reasons involves more than trying to recreate one nutrient with a gel cap.

A 12-month randomized trial of a sardine-enriched diet tested whether adding 200 g of sardines per week could delay type 2 diabetes in 152 adults aged 65 or older with prediabetes. Both groups received the same diabetes-prevention nutrition guidance; only the sardine group added sardines. The trial was designed around the possibility that sardines' omega-3 and taurine content might work separately or together. It was a diabetes-prevention study, not an AF trial, so it cannot answer the dose-and-arrhythmia question.

Supplements do not outrank the basics

One cardiovascular study offers a useful reality check. In 241 people with established coronary artery disease—203 men and 38 women—researchers randomized participants to 3.36 g per day of EPA+DHA or no omega-3 for 30 months. In their analysis of coronary artery calcium, higher exercise capacity predicted lower calcium scores in both sexes, while omega-3 consumption did not independently predict lower scores.

Coronary artery calcium is a structural marker, not an AF endpoint, and this finding does not test whether standard-dose fish oil causes arrhythmia. It does curb a familiar leap in logic: a supplement's absence of one harm does not make it a substitute for exercise.

Metabolic health may matter for AF through pathways that deserve direct study. In a retrospective TriNetX cohort, Wu et al. studied adults with both type 2 diabetes and AF. After matching, 11,194 patients were analyzed. Tirzepatide use was associated with a lower risk of a composite outcome of cardioversion, intravenous antiarrhythmic drug use, and AF ablation (hazard ratio 0.65; 95% confidence interval 0.55 to 0.76; P<0.001).

That result is an association from an observational study, not proof that tirzepatide—or dietary change—caused less AF. It does support a narrower point: the metabolic conditions that travel with AF are clinically modifiable. Whether dietary interventions can reduce AF events through similar pathways requires dedicated trials.

The practical verdict

If you take 1,500 mg per day or less of combined EPA and DHA and have no known AF, the largest available randomized-trial synthesis does not support stopping solely because of an AF scare. Treat that conclusion as a strong preliminary update, because the analysis remains a preprint.

If you take more than 1,500 mg per day, especially a 4-g regimen for cardiovascular disease, discuss AF risk with the clinician managing that treatment. The reported high-risk subgroup signal is meaningful enough to weigh against the reason for treatment.

For everyone else, fish remains a sensible food choice when it fits the diet—not because it has been proven to solve AF, but because it brings nutrients and protein that isolated omega-3 capsules do not. The capsule debate answers one safety question. It does not replace the rest of cardiovascular prevention.